Boston Scientific (NYSE:BSX) Director Sells $1,010,288.70 in Stock

Boston Scientific Corporation (NYSE:BSX) Director Ellen Zane sold 9,990 shares of the firm’s stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $101.13, for a total value of $1,010,288.70. Following the completion of the sale, the director directly owned 27,035 shares in the company, valued at $2,734,049.55. This trade represents a 26.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Boston Scientific Stock Performance

BSX opened at $100.55 on Friday. The firm has a market capitalization of $148.98 billion, a P/E ratio of 53.77, a price-to-earnings-growth ratio of 2.02 and a beta of 0.61. The stock’s 50 day moving average price is $100.87 and its two-hundred day moving average price is $102.25. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 12-month low of $83.38 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The firm had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The company’s revenue was up 20.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on BSX shares. Jefferies Financial Group reaffirmed a “hold” rating on shares of Boston Scientific in a report on Monday, July 21st. Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 11th. Leerink Partners lifted their price objective on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Robert W. Baird lifted their price objective on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Finally, Evercore ISI reissued an “outperform” rating on shares of Boston Scientific in a report on Wednesday, October 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, Boston Scientific presently has a consensus rating of “Buy” and a consensus price target of $123.77.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BSX. Steph & Co. acquired a new stake in Boston Scientific in the 3rd quarter valued at $25,000. Financial Consulate Inc. acquired a new stake in Boston Scientific in the 3rd quarter valued at $25,000. 1248 Management LLC acquired a new stake in Boston Scientific in the 1st quarter valued at $26,000. FWL Investment Management LLC acquired a new stake in Boston Scientific in the 2nd quarter valued at $26,000. Finally, Y.D. More Investments Ltd acquired a new stake in Boston Scientific in the 1st quarter valued at $27,000. Institutional investors own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.